A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy
Key facts
- Where
- Bari, Bergamo, Bologna, Brescia, Catania, Catanzaro, Florence, Foggia, Messina, Milan, Modena, Naples, Padova, Palermo, Pavia, Roma, Salerno, Sassari, Siena, Teramo, Torino, Treviso, Varese, and Verona, ItalySee the 24 sites
Where in Italy
- BariBari, ItalyTaking people
- BergamoBergamo, ItalyNot yet recruiting
- BolognaBologna, ItalyTaking people
- BresciaBrescia, ItalyNot yet recruiting
- CataniaCatania, ItalyNot yet recruiting
- CatanzaroCatanzaro, ItalyTaking people
- FlorenceFlorence, ItalyNot yet recruiting
- FoggiaFoggia, ItalyNot yet recruiting
- MessinaMessina, ItalyNot yet recruiting
- MilanMilan, ItalyTaking people
- ModenaModena, ItalyTaking people
- NaplesNaples, ItalyTaking people
- PadovaPadova, ItalyNot yet recruiting
- PalermoPalermo, ItalyTaking people
- PaviaPavia, ItalyNot yet recruiting
- RomaRoma, ItalyNot yet recruiting
- SalernoSalerno, ItalyNot yet recruiting
- SassariSassari, ItalyNot yet recruiting
- SienaSiena, ItalyNot yet recruiting
- TeramoTeramo, ItalyTaking people
- TorinoTorino, ItalyTaking people
- TrevisoTreviso, ItalyTaking people
- VareseVarese, ItalyTaking people
- VeronaVerona, ItalyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07214753
- Record updated
- 18 September 2026
- Original description
This is an observational, multicenter, prospective study on patients with severe eosinophilic asthma treated with benralizumab aimed at evaluating the achievement of partial and complete clinical remission.Read full original descriptionShow less
ItAlian, Multicenter, Observational, Prospective sTudy to Evaluate the acHievement of Clinical rEmission and immuNomodulation in Severe Eosinophilic Asthma Patients Treated With Benralizumab - the ATHENA Study
This is an observational, multicenter, prospective study on patients with severe eosinophilic asthma treated with benralizumab aimed at evaluating the achievement of partial and complete clinical remission.
Inclusion: Adults (≥ 18 years old) diagnosed with severe uncontrolled eosinophilic asthma; Benralizumab has been prescribed according to the approved label and local reimbursement criteria; Provision of signed Informed Consent Form (ICF) prior to any study-related activities; Benralizumab has been initiated within 7 days prior to study enrollment or is planned to be initiated within 7 days after enrollment (in the latter case, provided that the decision to prescribe benralizumab is made prior to the decision to enroll the patient in the study).
Exclusion: Benralizumab treatment within the 12 months prior to study enrollment and up to 8 days before enrollment; Previous participation (in the 12 months before enrollment), current participation or plan to participate within the follow up period to any other clinical trial; Previous or concomitant use of omalizumab, reslizumab, dupilumab, tezepelumab or mepolizumab without washout period as per clinical practice; patients with any clinical condition that may interfere with the subject's ability to cooperate and comply with the study procedures based on the Investigator's judgement; Contraindication to benralizumab as per current Summary of Product Characteristics (SmPC); Pregnant or lactating women.